Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 8 peer-reviewed journal articles Updated
Hepatology · AIH-PBC and AIH-PSC Overlap Syndrome

The Path Forward: Standard of Care and Treatment Options

At a Glance

The standard treatment for AIH-PBC and AIH-PSC overlap syndromes is combination therapy. This uses UDCA to protect the bile ducts alongside immunosuppressants like corticosteroids to reduce liver cell inflammation. The goal is to achieve completely normal liver enzyme and IgG levels.

Because overlap syndromes involve a dual attack on your liver, the standard of care requires a “two-pronged” approach. Treating only one side of the disease—either just the liver cells or just the bile ducts—is often insufficient. This dual treatment is known as Combination Therapy [1][2].

The First Line: Combination Therapy

For most patients with AIH-PBC or AIH-PSC overlap, the first goal of treatment is to achieve biochemical remission. This means your liver enzymes (ALT, AST, and ALP) and your IgG levels return to the normal range.

  1. Protecting the Bile Ducts (The Cholestatic Side):
    • Ursodeoxycholic acid (UDCA): This is a naturally occurring bile acid that helps protect the bile duct lining from damage. It is the cornerstone of treatment for the PBC or PSC component [1][3].
  2. Calming the Immune System (The Hepatitic Side):
    • Corticosteroids (e.g., Prednisone): These are used to quickly reduce inflammation in the liver cells.
    • Azathioprine: This is an immunosuppressant often used alongside steroids. The goal is frequently to use Azathioprine to maintain control so you can slowly lower (taper) your dose of steroids [1][3].

Second-Line: When First-Line Isn’t Enough

If your blood tests do not return to normal after several months of combination therapy, your doctor may consider “second-line” options for refractory cases [4].

  • For the AIH Component: If Azathioprine causes side effects or doesn’t work, Mycophenolate Mofetil (MMF) is a common alternative to suppress the immune system [5].
  • For the PBC/PSC Component: Fibrates (like Bezafibrate) or Obeticholic Acid (OCA) can sometimes be added to UDCA to further lower bile duct markers and protect the liver from scarring [6][7].

Essential Safety Protocols: Infections and Bones

Treating an autoimmune disease requires modifying the immune system, which introduces specific health risks you must actively manage with your doctor.

Immunosuppressant Safety

Medications like Prednisone and Azathioprine intentionally lower your immune response. This makes you more susceptible to infections.

  • Vaccines: Before starting heavy immunosuppression, you should review your vaccine status. It is highly recommended to be vaccinated against Hepatitis A and B, pneumonia, and the flu. Crucially, you must avoid “live” vaccines once on immunosuppressants.

Protecting Your Bones

Patients with overlap syndromes face a double risk for bone loss (osteoporosis). Bile duct damage causes poor absorption of Vitamin D and Calcium, and long-term corticosteroids actively weaken bones. You and your doctor should discuss regular bone density (DEXA) scans and starting Calcium and Vitamin D supplementation immediately to protect your skeletal health.

Why “Normal” is the Goal

Research shows that patients who achieve complete biochemical remission (normal lab numbers) through combination therapy have significantly fewer liver-related complications and a much better long-term outlook. By working closely with an experienced specialist, you can use these tools to effectively manage the disease and protect your liver [8][4].

Common questions in this guide

Why do I need combination therapy for an overlap syndrome?
Overlap syndromes involve a dual attack on both your liver cells and bile ducts. Combination therapy uses two types of medications, like UDCA for the bile ducts and immunosuppressants for the liver cells, to protect the entire organ simultaneously.
What is biochemical remission in overlap syndrome?
Biochemical remission means your liver enzymes (ALT, AST, and ALP) and IgG levels have returned to the normal range. Achieving this normal range is the primary goal of treatment and reduces the risk of long-term liver complications.
What happens if standard treatments for AIH-PBC don't work?
If standard therapies don't normalize your blood tests, your doctor may consider second-line options. These can include Mycophenolate Mofetil (MMF) for the autoimmune hepatitis component or Fibrates and Obeticholic Acid for the bile duct component.
Do I need special vaccines if I have an overlap syndrome?
Yes, before starting immunosuppressant medications like steroids or Azathioprine, you should ensure you are vaccinated against Hepatitis A, Hepatitis B, pneumonia, and the flu. However, you must avoid live vaccines once your immune system is suppressed.
How does overlap syndrome treatment affect my bone health?
Bile duct damage reduces your ability to absorb Vitamin D, while long-term corticosteroid use actively weakens bones. It is crucial to have regular bone density scans and take Calcium and Vitamin D supplements to prevent osteoporosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do my current lab results show 'biochemical remission,' meaning my ALT, AST, and ALP have reached the normal range, or are they just lower than before?
  2. 2.If my liver enzymes don't normalize with steroids and UDCA, are you prepared to discuss second-line options like Mycophenolate Mofetil or Fibrates?
  3. 3.How do we decide when it is safe to taper my steroid dose while ensuring my liver cells remain protected?
  4. 4.Given that I will be on immunosuppressants, should I receive vaccines like Hepatitis A, Hepatitis B, or the flu shot before I start?
  5. 5.How will we monitor and protect my bone density while I am on steroids and experiencing fat-soluble vitamin malabsorption?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (8)
  1. 1

    Primary cutaneous amyloidosis associated with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome and Sjögren syndrome: A case report.

    Yan X, Jin J

    Medicine 2018; (97(8)):e0004 doi:10.1097/MD.0000000000010004.

    PMID: 29465536
  2. 2

    A meta-analysis of ursodeoxycholic acid therapy versus combination therapy with corticosteroids for PBC-AIH-overlap syndrome: evidence from 97 monotherapy and 117 combinations.

    Zhang H, Li S, Yang J, et al.

    Przeglad gastroenterologiczny 2015; (10(3)):148-55 doi:10.5114/pg.2015.51187.

    PMID: 26516380
  3. 3

    Familial occurrence of autoimmune liver disease with overlapping features of primary biliary cholangitis and autoimmune hepatitis in a mother and her daughter.

    Omori K, Yoshida K, Yokota M, et al.

    Clinical journal of gastroenterology 2016; (9(5)):312-8 doi:10.1007/s12328-016-0676-1.

    PMID: 27503128
  4. 4

    Fulminant Primary Biliary Cholangitis-Autoimmune Hepatitis (PBC-AIH) Overlap Syndrome in a 27-Year-Old Woman With Childhood-Onset AIH: Steroid-Refractory Decompensation Necessitating Urgent Transplant Evaluation.

    Said E, Tafesse Y, Elbenawi HR, et al.

    Cureus 2025; (17(7)):e87519 doi:10.7759/cureus.87519.

    PMID: 40786261
  5. 5

    Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.

    Efe C, Taii HA, Ytting H, et al.

    Digestive diseases and sciences 2018; (63(5)):1348-1354 doi:10.1007/s10620-018-5011-x.

    PMID: 29569003
  6. 6

    Risk stratification and treatment of primary biliary cholangitis.

    Martínez J, Aguilera L, Albillos A

    Revista espanola de enfermedades digestivas 2019; (111(1)):63-70 doi:10.17235/reed.2018.5662/2018.

    PMID: 30338693
  7. 7

    Effective treatment of autoimmune hepatitis-primary biliary cholangitis overlap syndrome with obeticholic acid.

    Castro Limo JD, Romero-Gutiérrez M, Ruiz Martín J

    Revista espanola de enfermedades digestivas 2020; (112(9)):737 doi:10.17235/reed.2020.6883/2020.

    PMID: 32496125
  8. 8

    Efficacy and Safety of Immunosuppressive Therapy for PBC-AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study.

    Fan X, Zhu Y, Men R, et al.

    Canadian journal of gastroenterology & hepatology 2018; (2018()):1965492 doi:10.1155/2018/1965492.

    PMID: 30155449

This page provides educational information about treatment options for AIH-PBC and AIH-PSC overlap syndromes. Always consult your hepatologist or gastroenterologist before changing medications or receiving vaccinations.

Get notified when new evidence is published on Primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.